Amgen Inc. closed $68.59 short of its 52-week high ($346.85), which the company reached on July 25th.

Shares of Amgen Inc. AMGN inched 0.08% higher to $278.32 Tuesday, on what proved to be an all-around mixed trading session ...

Patients with recurrent platinum-sensitive ovarian cancer did just as well with cytoreductive surgery alone as they did with ...

"Importantly, although the most commonly considered osteoporotic fractures (hip, vertebral, forearm, humerus, and pelvis) ...

Shares of Amgen (NASDAQ: AMGN) are down by 6% in the last 30 days as I write this -- a larger-than-normal amount for a large ...

The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

AMGN's reasonable valuation, an interesting pipeline and continued top-line growth are good enough reasons to stay invested ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amgen Inc. (AMGN), Eaton Corp. plc ...

Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a ...

While most of this collection of Dow Industrials is too pricey and reveals only skinny dividends, one of the ten lowest ...

Unlike its rivals, which require weekly injections, MariTide offers the potential for monthly or less frequent dosing ...